IN2015DN01023A - - Google Patents

Info

Publication number
IN2015DN01023A
IN2015DN01023A IN1023DEN2015A IN2015DN01023A IN 2015DN01023 A IN2015DN01023 A IN 2015DN01023A IN 1023DEN2015 A IN1023DEN2015 A IN 1023DEN2015A IN 2015DN01023 A IN2015DN01023 A IN 2015DN01023A
Authority
IN
India
Prior art keywords
dosage forms
oral dosage
formulations
memantine
dementia
Prior art date
Application number
Inventor
Elena Kagan
Nitzan Shahar
Elina Haronsky
Gregg R Derosa
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IN2015DN01023A publication Critical patent/IN2015DN01023A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to oral dosage forms comprising Memantine or a pharmaceutically acceptable salt thereof pharmaceutical formulations comprising the oral dosage forms and methods for treating mild moderate or severe Alzheimer s dementia or neuropathic pain comprising the oral dosage forms and formulations.
IN1023DEN2015 2012-08-16 2013-08-16 IN2015DN01023A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261683875P 2012-08-16 2012-08-16
US201361833348P 2013-06-10 2013-06-10
PCT/US2013/055420 WO2014028878A1 (en) 2012-08-16 2013-08-16 Pharmaceutical compositions of memantine

Publications (1)

Publication Number Publication Date
IN2015DN01023A true IN2015DN01023A (en) 2015-06-26

Family

ID=49029259

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1023DEN2015 IN2015DN01023A (en) 2012-08-16 2013-08-16

Country Status (10)

Country Link
US (2) US20140050784A1 (en)
EP (1) EP2884967B1 (en)
CN (1) CN104755074A (en)
AU (1) AU2013302359A1 (en)
ES (1) ES2623176T3 (en)
IL (1) IL237139A0 (en)
IN (1) IN2015DN01023A (en)
MX (1) MX2015001917A (en)
RU (1) RU2015107517A (en)
WO (1) WO2014028878A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
AU2015274451C1 (en) 2014-06-11 2019-09-12 Massachusetts Institute Of Technology Residence structures and related methods
CN104586807B (en) * 2014-12-25 2018-03-30 广州帝奇医药技术有限公司 Sustained release preparation for treating Alzheimer's disease and preparation method thereof
US11576859B2 (en) 2015-10-23 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
CN108697649A (en) 2015-12-08 2018-10-23 林德拉有限公司 Geometric configuration for stomach resident system
WO2017205844A2 (en) 2016-05-27 2017-11-30 Lyndra, Inc. Materials architecture for gastric residence systems
AU2017336154B2 (en) * 2016-09-30 2023-11-09 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
CN107213130B (en) * 2017-05-12 2018-05-11 上海奥科达生物医药科技有限公司 A kind of Entecavir Pharmaceutical composition, preparation method and applications
JP7274428B2 (en) 2017-06-09 2023-05-16 リンドラ セラピューティクス， インコーポレイティド Gastric retention system with controlled release film
AU2019209740A1 (en) * 2018-01-19 2020-09-10 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Use of carrimycin or active ingredient thereof
WO2022025785A1 (en) * 2020-07-29 2022-02-03 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Pharmaceutical composition comprising memantine and citicoline

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4225730C2 (en) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Process for the preparation of solid dosage forms with protracted 2-stage release
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
CN1968684A (en) * 2004-06-17 2007-05-23 森林实验室公司 Modified release formulation of memantine
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006089066A1 (en) * 2005-02-15 2006-08-24 Neuromolecular Pharmaceuticals, Inc. Combinations therapy for treatment of demyelinating conditions
EP1898890A1 (en) 2005-06-16 2008-03-19 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
TWI491395B (en) * 2009-09-30 2015-07-11 Ct Lab Inc Oral dosage formulation containing both immediate-release and sustained-release drugs for treating neurodegenerative disorders
US20140004189A1 (en) * 2011-01-25 2014-01-02 Cadila Healthcare Limited Modified release pharmaceutical compositions memantine
TR201104108A2 (en) * 2011-04-27 2011-08-22 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Prolonged release memantine tablets.

Also Published As

Publication number Publication date
ES2623176T3 (en) 2017-07-10
US20170231927A1 (en) 2017-08-17
EP2884967A1 (en) 2015-06-24
AU2013302359A1 (en) 2015-03-19
CN104755074A (en) 2015-07-01
WO2014028878A1 (en) 2014-02-20
MX2015001917A (en) 2015-10-29
IL237139A0 (en) 2015-04-30
US20140050784A1 (en) 2014-02-20
RU2015107517A (en) 2016-10-10
EP2884967B1 (en) 2017-02-01

Similar Documents

Publication Publication Date Title
ZA202202711B (en) Sustained-release dosage forms of ruxolitinib
IN2015DN01023A (en)
IN2014DN10670A (en)
RS58104B1 (en) Pharmaceutical compositions for treating alzheimer's disease
NZ627980A (en) Pharmaceutical compositions containing dimethyl fumarate
IN2014MN02236A (en)
MX349224B (en) Pharmaceutical composition for use in the treatment of a neurodegenerative disease.
MX2014004196A (en) Rasagiline citramide.
MX347105B (en) Pharmaceutical compositions comprising hydromorphone and naloxone.
IL237730B (en) Treatment of mild and moderate alzheimer's disease
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
PH12015501402A1 (en) 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
PH12014502065A1 (en) Vesicular formulations
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MD4615C1 (en) Isolated solid form of anamorelin monohydrochloride, pharmaceutical composition and method of making a pharmaceutical dosage form comprising it
MX2015007945A (en) Uses and methods for the treatment of liver diseases or conditions.
MX366309B (en) Pharmaceutical composition for treating inflammation and pain.
WO2012174243A8 (en) D -serine for the treatment of visual system disorders
PH12019501070A1 (en) Sustained-release dosage forms of ruxolitinib
HK1202249A1 (en) Vesicular formulations